Manufacturer: Dragon Pharma
Pharmaceutical name: Modified GRF (1-29)
Pack: 1 vial (5 mg)
```html
CJC-1295 peptide with DAC, also referred to as DAC:GRF, is a synthetic version of a segment of the naturally occurring growth hormone releasing hormone (GHRH). The chemistry of CJC-1295 with DAC is centered around the initial 29 amino acids of GHRH, as these amino acids are essential for full biological efficacy.
However, this peptide has undergone further modifications, with four amino acids changed to enhance its stability and effectiveness compared to the original CJC-1295 without DAC. These alterations enable the peptide to bind permanently to the protein albumin in the body, thereby decreasing its degradation and oxidation, which improves its stability. Additionally, these modified amino acids boost the binding affinity to the GHRH receptor, enhancing its potency. GHRH is crucial for the natural secretion of growth hormone and is vital for optimal growth during developmental phases.
CJC-1295 functions by triggering the release of growth hormone through its interaction with GHRH receptors, promoting the secretion of various growth hormone peptides typically released by the pituitary gland. These hormones contribute to increased bone density and collagen production, as well as strengthening the immune system. They also facilitate the development of lean muscle mass.
CJC-1295 with DAC can be used in conjunction with growth hormone releasing peptides to optimize results from peptide cycling. It is often combined with growth hormone replacement peptides (GHRP) like GHRP-6 or GHRP-2. The simultaneous use of CJC-1295 DAC with GHRPs accelerates fat loss and weight management while promoting anabolic effects through growth hormone-induced fat breakdown. Overall, CJC-1295 with DAC enhances protein synthesis and supports the growth of lean muscle tissue. This peptide also aids in quicker recovery from injuries, reduces body fat, and increases muscle mass. The growth-stimulating traits of CJC-1295 DAC additionally support cell growth and division, benefiting skin health, healing processes, and immune system performance.
This peptide should not be mistaken for CJC-1295 without DAC, as their chemical characteristics are significantly different and can impact dosing. CJC-1295 DAC has a half-life of approximately 8 days post-injection. For optimal effects, CJC-1295 with DAC should be administered subcutaneously and can be injected weekly at doses of 100 mcg or 200 mcg, owing to its prolonged half-life. This peptide cycling approach with CJC-1295 DAC will yield an extended increase in growth hormone levels. A weekly injection of CJC-1295 with DAC can be combined (stacked) with other GHRPs, such as GHRP-6 or GHRP-2.
Numerous studies have reported the growth-stimulating effects and safety of GHRH given to children with growth hormone deficiency. Various treatment methods—such as intravenous pulses, intranasal delivery, subcutaneous injections, and continuous infusion—have been evaluated, showing that the growth-promoting effect of GHRH correlates with the dosage and frequency of administration. There have been no unexpected adverse reactions noted following long-term treatment, regardless of the delivery method. However, some minor side effects may arise, including fatigue, euphoria (head rush), water retention, and sensations of tingling or numbness. Adhering to the recommended dosage can help reduce the likelihood of side effects.
```